International Society for Stem Cell Application (ISSCA) Returns to Peru with WorldConference on Regenerative Medicine and Cellular Therapies
International Society for Stem Cell Application (ISSCA) Returns to Peru with World Conference on Regenerative Medicine and Cellular Therapies
Overview of the Conference
Miami, Florida – The International Society for Stem Cell Application (ISSCA), a distinguished division of the Global Stem Cells Group (GSCG), is excited to announce its highly anticipated international conference on Regenerative Medicine and Cellular Therapies. Scheduled to unfold in the dynamic city of Lima, Peru, this groundbreaking event will span two immersive days, from September 6th to 7th, 2024. Day one will be dedicated to enlightening conferences, while day two will offer hands-on sessions, providing attendees with a comprehensive learning experience.
Key Organizers and Participants
Renowned urologist Dr. Jorge Saldaña, certified by ISSCA and highly regarded in the region, will play a key role in organizing the conference. The event will also serve as the venue for Dr. Saldaña’s appointment as the director of the ISSCA chapter in Peru. This significant appointment is scheduled for September 6th, further underscoring his dedication to advancing regenerative medicine not only in Peru but also in neighboring regions of Latin America.
Objectives and Highlights
The conference aims to assemble leading scientists and medical professionals worldwide, offering a unique platform to explore and discuss the latest advancements in regenerative medicine. With an array of elite speakers, including distinguished scientists and physicians renowned for their contributions to the field, attendees can anticipate gaining profound insights into the cutting-edge clinical applications of stem cell therapies.
Innovations in Regenerative Medicine
Attendees are expected to be at the forefront of revolutionary technologies in regenerative medicine. From the latest breakthroughs reshaping healthcare to innovative tools enhancing clinical practice, participants will uncover advancements poised to elevate their practice and enhance patient care.
Comprehensive Learning Experience
This conference provides a holistic understanding of regenerative medicine, spanning foundational principles to cutting-edge applications. Attendees are anticipated to leave equipped with the essential knowledge to navigate the rapidly evolving landscape of regenerative medicine.
Hands-On Training Sessions
Beyond theoretical discourse, the conference offers invaluable hands-on training sessions led by ISSCA-certified instructors. Attendees will gain practical experience in both aesthetic and clinical applications of stem cell therapy, ensuring they leave equipped with skills ready for immediate implementation.
ISSCA’s Commitment to Peru
ISSCA is proud to bring its expertise back to Lima, Peru, reaffirming its presence in the southern cone with this global conference. Benito Novas, founder of Global Stem Cells Group and head of relationships of ISSCA, expresses his excitement, stating, “I’m thrilled to return to Peru with new technologies in the field of regenerative medicine. We will be providing local doctors and neighboring regions with the latest advancements in the field. Regenerative medicine is the future of healthcare as more research is conducted and products are developed to offer superior services.”
Expert Engagement and Practical Relevance
Benito adds, “The conference will feature world-renowned experts engaging directly with live trainees and patients to impart diverse cellular and procedural therapy techniques. These sessions will utilize locally available tools, ensuring practical applicability and relevance to the attendees’ contexts.”
ISSCA’s Global Recognition
As an acclaimed stakeholder in regenerative medicine and stem cell therapy, ISSCA offers a globally recognized certification to physicians and professionals, highlighting its fascinating track record in this highly sought-after field. According to Dr. Saldaña, “ISSCA has always been a pioneer in the world of regenerative medicine, serving as a worldwide reference. Having them here once again with their world conference is a fantastic opportunity, and I’m genuinely delighted to be part of this momentous event.”
Tailored for Local Trainees
The Conference considers the needs of local trainees using a thorough scheduling process. Initial consultations between the trainees and ISSCA will inform equipment and kits availability, materials, underlying costs, and any other needs to be met during the main event.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training. ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges, ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications. GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331.
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
New advances in osteoarthritis therapy with stem cells
Osteoarthritis is a rheumatic pathology that damages the articular cartilage. By joining two bones through the joint capsule, the joints are able to move, providing us with functional autonomy. An inner fluid called synovial fluid is usually found within joints, which is produced by the synovial membrane. Articular cartilage covers the ends of the bones that form the joint. As a result of damage to this articular cartilage, pain, stiffness, and functional impairment occur. Osteoarthritis is the most common joint disorder, usually beginning between the ages of 40 and 50, affecting to some degree almost everyone over the age of 80. Typically, osteoarthritis affects the spine, shoulders, fingers, hips, knees, and toe joints.
Stem cell therapies have the potential to treat a broad spectrum of diseases. Whether it’s rhizarthrosis, diabetes, neurodegenerative diseases, spinal cord injuries, or heart disease. By utilizing stem cells, regenerative medicine is capable of repairing tissues in affected areas. The main difference between lipo gem therapy and other treatments for osteoarthritis is that lipogem therapy regenerates cartilage, avoids surgery and its sequelae, and improves the quality of life for patients.
The potential for medical treatments with stem cells and their by-products is currently very high. In the field of sports medicine and traumatology, one of the most outstanding advances has been made for the first time in decades recently: Spanish scientists have achieved a degree of tendon regeneration in 100% of injured patients, resulting in a decrease in pain and a return to sport within two months, and just six months after the trial was completed.
A research performed by the Institute of Regenerative Tissue Therapy (ITRT), published by the prestigious American Journal of Sports Medicine. Demonstrates how this therapy regenerates chronic lesions in the patellar tendon and opens up a new therapeutic option for this tissue, which was considered impossible to regenerate.
In most patients, fat tissue can be harvested minimally invasively (under local or general anesthesia), providing a highly viable MSC population regardless of donor age. Similar to MSCs derived from other tissues, adipose tissue-derived MSCs have regenerative potential. As osteoarthritis is a very common joint disease, and knee osteoarthritis is the most common form, it is necessary to review scientific literature on osteoarthritis treatments with stem cells, like lipogems.
Lipogems Therapy
Lipogems therapy is a novel procedure that enhances the body’s natural ability to heal itself through the innovative power of science and biotechnology. The Lipogems method involves injecting mesenchymal stem cells into the joints. Adipose-derived mesenchymal stem cells have enormous regenerative potential. They also have a regenerative capacity independent of their age. Even older individuals can benefit from this procedure.
Injection of mesenchymal stem cells into the knee, particularly in the early stages of osteoarthritis, can stop the process of inflammation and degeneration, especially in the less advanced stages of the disease. In addition to preventing progressive physical deterioration of the articular cartilage, this treatment contributes significantly to a patient’s well-being and prevents the installation of knee prostheses.
Patellar tendinopathy, physiotherapeutic treatment and stem cell therapy
Injuries to the patellar tendon that connects the kneecap to the tibia are known as patellar tendinopathy or patellar tendinitis. The patellar tendon works with the muscles in the front of the thigh to extend the knee so you can kick, run and jump. Athletes who perform frequent jumping in their sports, such as basketball and volleyball, are most likely to suffer from patellar tendonitis. However, people who don’t engage in jumping sports may develop patellar tendonitis. Patients with patellar tendinitis usually begin treatment with physical therapy to stretch and strengthen their knee muscles.
Strength training with eccentric resistance is one of the most common treatments for tendinopathies. Alternatively, it has been demonstrated that bone marrow-derived mesenchymal stem cells (MSCs) can regenerate injured patellar tendons. Within six months of treatment, it has been observed that the structure of this tissue – which is always difficult to treat – is restored, reaching a regeneration of 40% in all injured persons, with a gradual improvement that eventually becomes complete.
It has been found that traditional management methods, including isometric or eccentric exercises, shock wave therapy, and even surgery, are not effective. As part of a rehabilitation program in chronic patellar tendinopathy, autologous expanded bone marrow mesenchymal stem cells (BM-MSC) or leukocyte-poor platelet-rich plasma (Lp-PRP) may be effective in reducing pain and improving activity levels. Traditional management, which includes isometric or eccentric exercises, shock wave therapy, and even surgery, has limited success. A combination of autologous expanded bone marrow mesenchymal stem cells (BM-MSCs) and leukocyte-poor platelet-rich plasma (Lp-PRP) and rehabilitation may reduce pain and improve activity levels in active participants with chronic patellar tendinopathy.
To learn more about stem cells, cellular therapies and keep up to date with all the information about regenerative medicine and its advances, sign up for our international certification in regenerative medicine at www.issca.us
- Published in Corporate News / Blog
ISSCA Announces Partnership with Turkish Stem Cell Society and Endorsement by Leading Turkish Universities for Regenerative Medicine Congress
Miami, Florida – The International Society for Stem Cell Application (ISSCA) is delighted to announce its strategic partnership with the Turkish Stem Cell Society, along with the prestigious endorsement of three of Turkey’s top universities: Yeditepe University, Atlas University and Marmara University. This collaboration marks a significant milestone in advancing the field of regenerative medicine and stem cell therapy in Turkey and beyond.
The annual Congress of Regenerative Medicine, scheduled to take place from November 10 to 12, 2023, will be hosted at the elegant Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey. This event is poised to serve as a pivotal platform for the exchange of groundbreaking advancements in stem cell therapy and regenerative medicine.
Partnership with Turkish Stem Cell Society and University Endorsements
The partnership with the Turkish Stem Cell Society underscores the commitment of ISSCA to advancing the field of regenerative medicine not only on a global scale but also within the vibrant Turkish scientific and medical community. Turkish Stem Cell Society has been at the forefront of research and innovation in stem cell therapy, making this collaboration a natural fit to foster greater knowledge sharing and cooperation.
Furthermore, ISSCA is honored to be endorsed by three of the most prestigious universities in Turkey:
Yeditepe University: Yeditepe University, a leading academic institution in Turkey, has a rich history of contributing to the fields of medicine and healthcare. Its endorsement of the Regenerative Medicine World Congress 2023 reaffirms the importance of this event in advancing the understanding of regenerative medicine.
Atlas University: Atlas University, with its commitment to research and innovation, plays a pivotal role in shaping the future of healthcare in Turkey. The university’s endorsement signifies the importance of regenerative medicine in modern medical practices.
Marmara University: Marmara University, recognized for its commitment to excellence in education, research, and innovation, is yet another prestigious institution supporting the congress. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has become a center of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure collaborate with Global Stem Cells Group to drive advances in regenerative medicine within the center, which is located on the university’s main campus.
World Congress Highlights
Representing over 35 countries, the Regenerative Medicine World Congress 2023 is set to be a hub of medical expertise. Renowned doctors and scientists from around the globe are expected to converge to share their insights and findings through evidence-based research presentations. This three-day symposium is designed to reshape medical understanding and ignite innovative possibilities.
A key feature of the congress is the immersive hands-on training, provided by ISSCA-certified instructors. Participants are expected to have the opportunity to delve into clinical and aesthetic applications of stem cell therapy over a single intensive day. This specialized training, guided by experts with extensive experience, equips attendees with practical skills that can be directly applied in their medical practice.
Collaboration and Appreciation
ISSCA is thrilled about the collaborative partnership with the Turkish Stem Cell Society and deeply appreciates the endorsements from Yeditepe University, Atlas University, and Marmara University. We look forward to the Regenerative Medicine World Congress 2023 as a significant step towards advancing the field of regenerative medicine. Your support and participation are invaluable, and we are genuinely excited to embark on this journey together.
For more information about the Regenerative Medicine World Congress 2023 and to register for this groundbreaking event, please visit www.issca.com
About the Turkish Stem Cell Society:
The Turkish Stem Cell Society is a leading organization dedicated to promoting ethical and responsible stem cell research and therapy in Turkey. They are committed to advancing scientific knowledge and education in the field of stem cells and regenerative medicine.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
